company background image
897

Wai Yuen Tong Medicine HoldingsSEHK:897 Stock Report

Last Price

HK$0.30

Market Cap

HK$375.7m

7D

1.7%

1Y

-17.6%

Updated

19 Jan, 2022

Data

Company Financials
897 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

897 Stock Overview

Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicine, western pharmaceutical products, and health food and personal products in Hong Kong, Mainland China, Macau, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Wai Yuen Tong Medicine Holdings
Historical stock prices
Current Share PriceHK$0.30
52 Week HighHK$0.51
52 Week LowHK$0.28
Beta1.03
1 Month Change-3.18%
3 Month Change-10.29%
1 Year Change-17.57%
3 Year Change22.49%
5 Year Change-15.28%
Change since IPO-100.00%

Recent News & Updates

Aug 18
Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now

Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now

CEO Ching Ho Tang has done a decent job of delivering relatively good performance at Wai Yuen Tong Medicine Holdings...

Mar 17
Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

897HK PharmaceuticalsHK Market
7D1.7%-0.2%-0.2%
1Y-17.6%-23.1%-16.2%

Return vs Industry: 897 exceeded the Hong Kong Pharmaceuticals industry which returned -20.6% over the past year.

Return vs Market: 897 underperformed the Hong Kong Market which returned -16% over the past year.

Price Volatility

Is 897's price volatile compared to industry and market?
897 volatility
897 Average Weekly Movement6.5%
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement6.7%
10% most volatile stocks in HK Market13.2%
10% least volatile stocks in HK Market3.0%

Stable Share Price: 897 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 897's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
18971,825Ching Ho Tanghttps://www.wyth.net

Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicine, western pharmaceutical products, and health food and personal products in Hong Kong, Mainland China, Macau, and internationally. The company offers Chinese medicines and health food products under the Wai Yuen Tong brand name; and western pharmaceutical and personal care products under the Madame Pearl’s and Pearl’s brands. It also engages in the investment, holding, and selling of properties; provision of financial services; and agricultural produce exchange market operation.

Wai Yuen Tong Medicine Holdings Fundamentals Summary

How do Wai Yuen Tong Medicine Holdings's earnings and revenue compare to its market cap?
897 fundamental statistics
Market CapHK$375.65m
Earnings (TTM)-HK$134.97m
Revenue (TTM)HK$1.26b

0.3x

P/S Ratio

-2.8x

P/E Ratio

Valuation

Is Wai Yuen Tong Medicine Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 897 (HK$0.31) is trading below our estimate of fair value (HK$0.79)

Significantly Below Fair Value: 897 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 897 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Pharmaceuticals industry average.

PE vs Market: 897 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 897's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 897 is good value based on its PB Ratio (0.1x) compared to the HK Pharmaceuticals industry average (1.1x).


Future Growth

How is Wai Yuen Tong Medicine Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

8.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wai Yuen Tong Medicine Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Wai Yuen Tong Medicine Holdings performed over the past 5 years?

10.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 897 is currently unprofitable.

Growing Profit Margin: 897 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 897 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.2% per year.

Accelerating Growth: Unable to compare 897's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 897 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.8%).


Return on Equity

High ROE: 897 has a negative Return on Equity (-4.47%), as it is currently unprofitable.


Financial Health

How is Wai Yuen Tong Medicine Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 897's short term assets (HK$3.3B) exceed its short term liabilities (HK$2.4B).

Long Term Liabilities: 897's short term assets (HK$3.3B) exceed its long term liabilities (HK$1.6B).


Debt to Equity History and Analysis

Debt Level: 897's net debt to equity ratio (27.4%) is considered satisfactory.

Reducing Debt: 897's debt to equity ratio has increased from 28.4% to 45.4% over the past 5 years.

Debt Coverage: 897's debt is not well covered by operating cash flow (10.6%).

Interest Coverage: 897's interest payments on its debt are not well covered by EBIT (1x coverage).


Balance Sheet


Dividend

What is Wai Yuen Tong Medicine Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 897's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 897's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 897's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 897's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 897 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 897's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Ching Ho Tang (59 yo)

3.75yrs

Tenure

HK$8,178,000

Compensation

Mr. Ching Ho Tang, GBS, SBS, JP is Chairman of China Agri-Products Exchange Limited since February 8, 2021. Mr. Tang Co-founded Wang On Group Ltd., in 1987 and served as its Managing Director. Mr. Tang was...


CEO Compensation Analysis

Compensation vs Market: Ching Ho's total compensation ($USD1.05M) is above average for companies of similar size in the Hong Kong market ($USD233.34K).

Compensation vs Earnings: Ching Ho's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 897's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

Experienced Board: 897's board of directors are seasoned and experienced ( 15.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Wai Yuen Tong Medicine Holdings Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Wai Yuen Tong Medicine Holdings Limited
  • Ticker: 897
  • Exchange: SEHK
  • Founded: 1897
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$375.651m
  • Shares outstanding: 1.23b
  • Website: https://www.wyth.net

Number of Employees


Location

  • Wai Yuen Tong Medicine Holdings Limited
  • Skyline Tower
  • Suite 3101, 31st Floor
  • Kowloon Bay
  • Kowloon
  • Hong Kong

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 15:38
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.